Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Focusing on its New Subsidiaries and Intellectual Property
Lexaria has its patented DehydraTECH drug delivery platform The company’s technology is a complementary layer that works with the other research being done on cannabinoids Lexaria has a robust IP portfolio and four new subsidiary companies A drug delivery platform pioneer, Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its DehydraTECH technology. The company’s technology changes the way in which edible cannabinoids absorb into the body. The DehydraTECH drug delivery platform is patented for cannabidiol and all other non-psychoactive cannabinoids and enables the transportation of bioactive substances via oral ingestion. A research-driven enterprise, Lexaria Bioscience is based…
